Researchers seeking to source CJC-1295 DAC online require high-purity, fully verified reagents backed by comprehensive analytical documentation. PX1 Research manufactures premium-grade CJC-1295 with Drug Affinity Complex (DAC) in USA-based, GMP-compliant facilities to ensure absolute lot-to-lot consistency for preclinical study.
Researchers seeking to source CJC-1295 DAC online require high-purity, fully verified reagents backed by comprehensive analytical documentation. PX1 Research manufactures premium-grade CJC-1295 with Drug Affinity Complex (DAC) in USA-based, GMP-compliant facilities to ensure absolute lot-to-lot consistency for preclinical study.
When investigators search to buy CJC-1295 DAC online (cjc 1295 dac online kaufen), securing analytical-grade material with verifiable purity is the critical first step. CJC-1295 DAC is a synthetic growth hormone-releasing hormone (GHRH) analog engineered with a Drug Affinity Complex (DAC) moiety that covalently binds to endogenous serum albumin, substantially extending its plasma half-life in laboratory models. The compound is supplied strictly as a lyophilized peptide reagent for in vitro and preclinical research applications.
To maintain rigorous scientific standards, research institutions must avoid non-certified suppliers that fail to provide lot-specific documentation. At PX1 Research, every batch of CJC-1295 DAC undergoes rigorous verification, including reversed-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry (MS), ensuring qualified laboratories receive reagents exceeding 99% purity without chemical contaminants or unreacted side products.
CJC-1295 DAC is a modified 29-amino-acid peptide derived from the human GHRH sequence (1-29), optimized at specific amino acid residues to increase resistance to enzymatic degradation. The native peptide sequence undergoes substitution at positions 2, 8, 15, and 27 (D-Ala2, Gln8, Ala15, Leu27) to neutralize cleavage by dipeptidyl peptidase-IV (DPP-IV), a primary serum protease that rapidly inactivates native peptide hormones in physiological buffers.
The primary structural differentiator of CJC-1295 DAC is the addition of a reactive bioconjugate linker—maleimidopropionic acid—attached to the lysine residue at the C-terminus. In preclinical bioassays, this reactive electrophilic group forms a stable covalent thioether bond with the free Cys34 thiol group of serum albumin. By utilizing albumin as an endogenous carrier molecule, the effective half-life of the construct expands from minutes to several days, permitting sustained signal transduction at pituitary target sites during long-term growth hormone secretagogues evaluation.
At the cellular level, CJC-1295 DAC functions as a selective agonist at the GHRH receptor (GHRHR), a class B G-protein-coupled receptor predominantly localized on anterior pituitary somatotrophs. Upon ligand binding, GHRHR undergoes a conformational shift that activates intracellular heterotrimeric G proteins, specifically the Gs alpha subunit. This activation stimulates transmembrane adenylyl cyclase, converting adenosine triphosphate (ATP) into cyclic adenosine monophosphate (cAMP).
Elevated intracellular cAMP concentrations subsequently activate protein kinase A (PKA), driving the phosphorylation of the cAMP-response element-binding protein (CREB). CREB translocates to the nucleus to induce transcription of the growth hormone gene, stimulating pulsatile biosynthesis and regulated secretion of growth hormone. Because of the covalent albumin binding imparted by the DAC modification, receptor engagement remains continuous, providing extended physiological stimulation that can be monitored across longitudinal preclinical bioassays within our broader research library.
Preclinical studies evaluating CJC-1295 DAC demonstrate its capacity to elicit sustained elevations in both serum growth hormone (GH) and insulin-like growth factor 1 (IGF-1). In rodent and non-human primate models, a single administration of CJC-1295 DAC resulted in dose-dependent increases in baseline GH levels, maintaining elevated concentrations without abolishing the natural pulsatile nature of endogenous hormone release.
Research literature emphasizes that the primary downstream mediator of GH action is hepatic IGF-1. In rodent bioassays evaluating cellular proliferation and tissue regeneration markers, sustained GHRHR stimulation via CJC-1295 DAC led to a sustained, multi-day elevation of plasma IGF-1 concentrations. This continuous trophic axis stimulation has made CJC-1295 DAC a standard reference standard for investigators studying cellular repair mechanisms, protein synthesis pathways, and metabolic homeostasis in animal models.
Understanding the biochemical distinctions between GHRH analogs is essential when structuring experimental protocols. While CJC-1295 DAC incorporates the albumin-binding maleimide linker, CJC-1295 No DAC (also referred to as Modified GRF 1-29) lacks this conjugate. Consequently, Modified GRF 1-29 exhibits a brief elimination half-life of approximately 30 minutes in animal serum, necessitating frequent administration to mimic short physiological GHRH spikes. Researchers seeking acute receptor activation profiles often choose short-acting analogs, whereas chronic signaling studies rely on the extended kinetics of the DAC variant.
When comparing secretagogue classes across our catalog of all peptides, investigators frequently evaluate GHRH analogs alongside growth hormone secretagogue receptor (GHSR) agonists like Ipamorelin or specialized GHRH peptides such as Tesamorelin. While GHRH analogs bind directly to GHRHR to promote transcriptional GH synthesis, ghrelin mimetics act via the GHSR-1a pathway to trigger immediate peptide release. Combining these distinct mechanisms in dual-agonist preclinical protocols often demonstrates synergistic GH release in somatotroph cell cultures.
When ordering research reagents online (cjc 1295 dac online kaufen), verifying product purity and batch integrity is vital to prevent experimental artifact. Low-grade commercial peptides frequently contain residual synthesis solvents, trifluoroacetate (TFA) salts, truncated peptide sequences, or bacterial endotoxins that interfere with cell viability assays and receptor binding studies.
PX1 Research enforces stringent quality control mandates across every production run. All synthesis takes place in USA-based, ISO 17025-accredited and GMP-compliant facilities. Every lot is subjected to dual-stage analytical testing: reversed-phase HPLC establishes chemical purity (guaranteed >99%), while electrospray ionization mass spectrometry (ESI-MS) confirms exact molecular mass and sequence fidelity. These lot-specific Certificates of Analysis (COAs) are publicly accessible to ensure full analytical transparency.
In cell culture work and sensitive in vivo research models, bacterial lipopolysaccharide (LPS) contamination poses a significant risk to data integrity. Endotoxins activate Toll-like receptor 4 (TLR4) on macrophage and immune cell membranes, triggering systemic inflammatory cascades that obscure primary target outcomes in peptide bioassays.
PX1 Research conducts quantitative Chromogenic Recombinant Factor C (rFC) or Limulus Amebocyte Lysate (LAL) testing on all peptide batches to ensure endotoxin levels remain strictly below Industry-standard preclinical thresholds (<0.01 EU/mg). Furthermore, lyophilized powders undergo sterile filtration prior to final freeze-drying in ultra-clean ISO Class 5 environments, delivering a stable, sterile reagent ready for reconstitution in aseptic laboratory settings.
Proper handling and storage are required to maintain the structural integrity of CJC-1295 DAC. Lyophilized peptide vials should be stored upon arrival at -20°C or -80°C in a desiccated environment to prevent moisture condensation, which can accelerate peptide hydrolysis.
For laboratory reconstitution, researchers should utilize sterile bacteriostatic water (containing 0.9% benzyl alcohol) or sterile endotoxin-free phosphate-buffered saline (PBS), depending on the experimental model. The solvent should be introduced gently along the glass vial wall rather than sprayed directly onto the peptide cake. Gentle swirl mixing is recommended; vigorous vortexing or mechanical agitation must be avoided as it disrupts fragile secondary structures. Once reconstituted, liquid solutions should be aliquoted into single-use microcentrifuge tubes to prevent degradation caused by repeated freeze-thaw cycles, and kept at 4°C for short-term evaluation (up to 7 days) or -80°C for extended storage.
Academic institutions, biotechnology firms, and contract research organizations (CROs) require dependable supply chains and scalable procurement options. PX1 Research maintains full batch traceability from raw amino acid starting materials through final lyophilization and packaging.
Through our dedicated wholesale portal, institutional partners can establish recurring supply schedules, secure high-volume lot reservations for long-term longitudinal studies, and obtain customized analytical documentation. Whether sourcing single analytical standards or bulk quantities for high-throughput screening, PX1 Research provides reliable domestic fulfillment with same-day shipping (Monday–Friday) from our CA and AZ logistics hubs.
What is CJC-1295 DAC?
CJC-1295 DAC is a synthetic, 29-amino-acid growth hormone-releasing hormone (GHRH) analog conjugated with a Drug Affinity Complex (maleimidopropionic acid). It is designed for laboratory research use only to study sustained GHRH receptor signaling.
How does the DAC moiety alter the peptide's pharmacokinetics?
The Drug Affinity Complex (DAC) covalently binds to circulating serum albumin at the Cys34 residue in laboratory models. This albumin conjugation protects the peptide from renal clearance and enzymatic degradation, extending its elimination half-life significantly compared to non-DAC analogs.
What analytical testing is performed on PX1 Research CJC-1295 DAC?
Every lot of CJC-1295 DAC undergoes analytical testing via RP-HPLC to verify >99% chemical purity, mass spectrometry to confirm exact molecular weight, and LAL assays to ensure low endotoxin levels (<0.01 EU/mg).
How should lyophilized CJC-1295 DAC be stored in the lab?
Lyophilized vials should be stored at -20°C or -80°C in a dry environment. Reconstituted solution aliquots should be stored at -80°C to prevent hydrolysis and maintain bioactivity across multiple assay runs.
What is the difference between CJC-1295 DAC and CJC-1295 No DAC?
CJC-1295 DAC contains a bioconjugate linker that binds serum albumin for extended half-life, whereas CJC-1295 No DAC (Modified GRF 1-29) lacks this linker and exhibits a short half-life of roughly 30 minutes in preclinical models.
Can PX1 Research ship CJC-1295 DAC internationally?
PX1 Research ships domestically within the USA with same-day dispatch (Monday–Friday) from California and Arizona facilities. Qualified international research entities should check local regulatory requirements for importing laboratory reagents.
What reconstituting solvents are recommended for in vitro studies?
Bacteriostatic water (0.9% benzyl alcohol) or sterile endotoxin-free PBS are standard diluents for laboratory reconstitution. Solvents should be added carefully to avoid foaming or mechanical shear stress.
Is CJC-1295 DAC suitable for human clinical use or personal administration?
No. CJC-1295 DAC supplied by PX1 Research is strictly designated for laboratory research use only and in vitro assays. It is not intended for human or animal diagnostic or therapeutic application.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.